Cara Therapeutics, Inc. Cara Therapeutics, Inc.

Cara Therapeutics, Inc.

CARA

Helyezés a részvények között #9916
Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating... Cara Therapeutics, Inc. is an early-stage biopharmaceutical firm operating primarily within the United States. Its core business involves discovering and commercializing novel drug compounds, with a particular emphasis on addressing itching (pruritus) and pain by selectively modulating kappa opioid receptors. The company's therapeutic pipeline includes potential medicines designed to interact with the body's peripheral nervous system and immune cells. KORSUVA (difelikefalin), an injectable formulation, stands as their flagship product. It is approved for treating moderate-to-severe pruritus linked to chronic kidney disease in adult patients undergoing hemodialysis. Additionally, Cara Therapeutics is advancing an oral version of KORSUVA (difelikefalin) through its pipeline. This oral candidate has successfully completed Phase II clinical trials for relieving pruritus associated with atopic dermatitis and chronic kidney disease not requiring dialysis (NDD-CKD). It is also currently undergoing Phase II evaluation for pruritus related to chronic liver disease (specifically primary biliary cholangitis) and for notalgia paresthetica. The company has established international licensing agreements: one with Maruishi Pharmaceutical Co., Ltd for the development, production, and commercialization of difelikefalin-containing products targeting acute pain and uremic pruritus in Japan, and another with Chong Kun Dang Pharmaceutical Corporation for similar activities concerning difelikefalin products in South Korea. Cara Therapeutics, Inc. was established in 2004 and is headquartered in Stamford, Connecticut.
Részvényárfolyam
$15.96
Utolsó szinkronizálás: 2025-04-15
Piaci kapitalizáció
$875.31M
Változás (1 nap)
-4.14%
Változás (1 év)
-0.19%
Ország
US
Kereskedés Cara Therapeutics, Inc. (CARA)

Kategória

Healthcare
Cara Therapeutics, Inc. (CARA) osztalékhozamának története
Cara Therapeutics, Inc. (tőzsdei szimbólum: CARA) osztalékhozama (TTM) 2026 állapot szerint: 0
Átlagos osztalékhozam az elmúlt 5 évben: 0.00%
Cara Therapeutics, Inc. (CARA) osztalékhozamainak története 2026 és 2026 között
Éves záró osztalékhozam (TTM)
Év Osztalékhozam Változtassa meg
Nincs elég adat a megadott dátumokhoz.
Hasonló cégek vagy versenytársak osztalékhozamai (TTM)
Vállalat Osztalékhozam Ország
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL